Evercore ISI analyst Duane Pfennigwerth maintained a Buy rating on United Parcel (UPS – Research Report) yesterday and set a price target of $255.00. The company’s shares closed last Monday at $205.21.
According to TipRanks.com, Pfennigwerth is a 1-star analyst with an average return of -1.6% and a 39.7% success rate. Pfennigwerth covers the Industrial Goods sector, focusing on stocks such as Controladora Vuela Compania de Aviacion SAB de CV, Sun Country Airlines Holdings, and Allegiant Travel Company.
Currently, the analyst consensus on United Parcel is a Moderate Buy with an average price target of $241.35.
Based on United Parcel’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $27.77 billion and net profit of $3.09 billion. In comparison, last year the company earned revenue of $24.9 billion and had a GAAP net loss of $3.35 billion.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UPS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1907, Georgia-based United Parcel Service, Inc. is the world’s largest package delivery company and a leading provider of global supply chain management solutions. The company also operates one of the largest airlines in the world and has the world’s largest fleet of alternative-powered vehicles. The company operates through three segments: U.S. Domestic Package, International Package, and Supply Chain and Freight.
Read More on UPS:
- Evercore ISI Sticks to Their Buy Rating for F5 Networks (FFIV)
- Darden (DRI) Receives a Hold from Evercore ISI
- Evercore ISI Reaffirms Their Buy Rating on Brinker International (EAT)
- Analysts Offer Insights on Healthcare Companies: Calithera Bio (CALA), Apellis Pharmaceuticals (APLS) and BridgeBio Pharma (BBIO)
- Australia and New Zealand Banking Group Limited (ANEWF) Receives a Buy from Bell Potter